Skip to main content
NKTR logo

NKTR · Nektar Therapeutics

Track NKTR — free
$35.91 -0.53 (-1.45%) At close · Nov 17
Market Cap
$1.23B
Shares
34.21M
Volume · Nov 17 731.15K Avg daily vol (3M) 1.1M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$35.91 Open$36.31 Day$35.41–36.50 52W close$35.12–100.35 Avg vol 30d815K Short int6.8M · 19.8% of shares · 10.3d Short vol48% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 13

Up next

Mar 11, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 13
Current report 8-K Events of Nov 12
Cash runway expected past Phase 3 ZENITH AD readouts

Nektar Therapeutics reported $952.9 million in cash and investments as of September 30, 2026. Its cash runway is expected into the third quarter of 2028, past Phase 3 ZENITH AD readouts in atopic dermatitis in the summer of 2028.

Regulation FD disclosure
2 source passages
In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the “Company”) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with its prior guidance, the Company expects that this cash balance will extend its cash runway into the third quarter of 2028 past the initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis in the summer of 2028. Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Phase 3 expansion amid $952.9 million cash and investments

Nektar Therapeutics initiated three Phase 3 ZENITH AD trials, plans ZENITH AA-1 for December 2026, and reported $952.9 million in cash and marketable securities at September 30, 2026.

Revenue $9.39M ▼ 20.4% Net loss $55.65M Diluted EPS -$1.63
Read from the MD&A section
4 source passages
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. We have initiated three global registrational trials (ZENITH AD-1, ZENITH AD-2 and ZENITH AD-3) in the Phase 3 ZENITH AD program for rezpegaldesleukin. We intend to initiate a global registrational trial (ZENITH AA-1) in December 2026 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe alopecia areata. At September 30, 2026, we had approximately $952.9 million in cash and investments in marketable securities. Open the document at this passage
Nov 12
Earnings call
RESPEG Phase 3 advances with $953 million cash

RESPEG entered global Phase 3 studies for atopic dermatitis, with the alopecia areata study planned for December and data expected in summer 2028. The company ended Q3 2026 with $953 million in cash and investments and no debt.

4 source passages
Our global phase 3 studies in ectopic dermatitis have started, and our phase 3 study in alopecia areata is on track to start in December, earlier than was originally planned. We anticipate our first top-line data readouts for the ectopic dermatitis studies will be in the summer of 2028. RESPEG's novel TREG mechanism offers a critically important therapeutic modality for patients and one that is currently missing from the treatment armamentarium. We ended the third quarter of 2026 with approximately $953 million in cash and investments with no debt on our balance sheet. Open the document at this passage
Nov 12
Current report 8-K
Rezpegaldesleukin enters Phase 3 as cash reaches $952.9 million

Nektar Therapeutics reported that rezpegaldesleukin entered Phase 3 development, while cash and investments in marketable securities reached $952.9 million on September 30, 2026; third-quarter revenue was $9.4 million and net loss was $55.7 million.

Financial results
5 source passages
Nektar Therapeutics Announces Third Quarter 2026 Financial Results “This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development,” said Howard Robin, President and Chief Executive Officer of Nektar. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025. Revenue in the third quarter of 2026 was $9.4 million as compared to $11.8 million in the third quarter of 2025. Net loss for the third quarter of 2026 was $55.7 million or $1.63 basic and diluted net loss per share as compared to a net loss of $35.5 million or $1.87 basic and diluted loss per share in the third quarter of 2025. Open the document at this passage
Oct 1
Investor event
Analyst and Investor Event at EADV

Nectar reported that ResPeg maintained SALT20 responses in 63% of responders six months after treatment; the planned Phase III will advance 24 micrograms per kilogram every two weeks for 52 weeks, enrolling approximately 850 patients in early 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$52.19M
Trailing 12 months
Net income (TTM)
−$177.26M
Trailing 12 months
Revenue growth YoY
-20.4%
Year over year
Operating margin
-319.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+80.4%
Year over year · more shares
Price change (1Y)
-39.7%
Trailing year
Short interest
19.8%
Latest settlement · 10.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Nektar advanced rezpegaldesleukin into all three Phase 3 atopic dermatitis trials, moved the alopecia areata trial forward, reported positive Phase 2 results and ended the quarter with approximately $953 million of cash and investments and no debt. Revenue declined while operating expenses and net loss increased as Phase 3 development advanced, and clinical development retains a high risk of failure with no assurance of regulatory approval.

Bullish
  • + All three global ZENITH AD registrational trials have been initiated.
  • + The global ZENITH AA registrational trial is on track to start in December, earlier than previously planned.
  • + The Phase 2b REZOLVE-AD study met all primary and key secondary endpoints on the 24 micrograms per kilogram every-two-week regimen.
  • + Alopecia areata responses were maintained after treatment discontinuation, and hair regrowth continued to improve during six months off treatment.
  • + Nektar ended the third quarter with approximately $953 million in cash and investments and no debt.
  • + Nektar plans a proof-of-concept study of rezpegaldesleukin in approximately 30 patients with vitiligo.
Bearish
  • − Third-quarter revenue declined to $9.4 million from $11.8 million in the prior-year quarter.
  • − Third-quarter operating costs and expenses increased to $67.2 million from $43.5 million in the prior-year quarter.
  • − Third-quarter R&D expense increased to $44.1 million from $27.3 million in the prior-year quarter.
  • − The company expects fourth-quarter R&D expense to increase because of clinical enrollment, startup and CMC activities.
  • − Third-quarter net loss increased to $55.7 million from $35.5 million in the prior-year quarter.
  • − Clinical development remains subject to a high risk of failure and no assurance of regulatory approval.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −45%
below
Price vs 50-day avg −23%
below
RSI (14) 34
neutral
MACD trend Positive
52-week position 1%
near low
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −45%
trailing
YTD return −15%
this year
Relative strength −42%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $47 › 200d $65 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
19.78% of shares out · ▼ -3.3% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
248 holders — near 3-yr high, broad support
Squeeze score 70
elevated · 0–100
Fundamentals
Weak
Revenue growth +86%
Y/Y
EPS growth −12%
Y/Y
Free cash flow $-208.7M
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −64%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the Earnings Call filed Nov 12, 2026
end 2026
Cash and investments at least $840M
for the year
Non-cash royalty revenue $38M
Non-cash interest expense $28M
full-year
R&D expense Lowered $185M – $200M
Aug 13, 2026 $210M – $230M changed to Nov 12, 2026 $185M – $200M
Non-cash depreciation And stock-based compensation expense $5M – $10M
full year 2026
G&A expenses Raised $65M
Aug 13, 2026 $60M – $65M changed to Nov 12, 2026 $65M
Previous outlook earlier release · from the Earnings Call filed Aug 13, 2026

Still-open targets the latest release did not restate under the same label.

Cash and investments · year-end 2026 $815M – $840M
Non-cash interest expense · 2026 $30M – $35M
Guided vs delivered · last 2 settled
GAAP revenue full year 2021
guided $100M
$101.91M Beat +1.9%
Full year 2020 GAAP revenue full year 2020
guided $140M – $145M
$152.92M Beat +7.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−45% Bearish
Price vs 50-day avg
−23% Bearish
RSI (14)
34 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $47 › 200d $65 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
19.78% of shares out · ▼ -3.3% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
248 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $35 Now $36 · 1% Range high $100
vs 200-day avg -45% vs 50-day avg -23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash and investments in marketable securities $952.9M September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NKTR
Nektar Therapeutics
this stock
$1.23B -15.1% +86.0% — 19.8%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
248
% held
104.7%
Net QoQ
-38.7K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
178
View
Short & Settlement
Short Interest Falling
Shares short
6.8M
Days to cover
10.3d
Change
-231.7K sh
View
Short Volume
Short vol %
48%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
3.2K
Value
$118.8K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
54.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$55.2M
Net income (FY)
$-164.1M
EPS diluted
$-9.73
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
27

Nektar Therapeutics reported $952.9 million in cash and investments as of September 30, 2026. Its cash runway is expected into the third quarter of 2028, past Phase 3 ZENITH AD readouts in atopic dermatitis in the summer of 2028.

View
Proposed Sales
Value
$15.4K
Shares
429
Filed
Nov 17, 2026
View
Exempt Offerings
Offering
$30.0M
Filed
Mar 19, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Nektar Therapeutics Announces Thi…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
NKTR -5.0% -8.4% -44.8% -7.6% -15.1%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -2.6% -3.7% -41.8% -4.5% -22.5%
Key facts CIK 906709 CUSIP 640268306 13F (30d) 280 filings 243 filers Visit website Investor relations